Interface Bio

About us

The future of medicine is defined and driven by the interfaces of human biology

Our Mission

Tackling complex inflammatory diseases together

We are on a mission to create safe and effective next-generation immunotherapies by leveraging the power of biological evolution and modern machine learning. We aim to bring our expertise and values to truly explore and discover the potential of natural-derived products for human diseases.

Intention

Grit

Respect

Founders

Interface Bio was co-founded by two Stanford PhDs with a shared belief that the interface and synergy of biological evolution, metabolomics, and AI would lead to life-changing medicines.

Hannah C. Wastyk, Ph.D.

Co-founder and CEO

Will Van Treuren, Ph.D.

Co-founder and CSO

Hannah C. Wastyk, Ph.D.

Co-founder and CEO

Will Van Treuren, Ph.D.

Co-founder and CSO

Hannah C. Wastyk, Ph.D.

Co-founder and CEO

Hannah graduated from Stanford in 2021 with her PhD in Bioengineering. Armed with a background in experimental biochemistry, she shifted her focus during grad school to study the causal relationships between the human microbiome and immune system using multi-omics data sets with machine learning and statistical methods.

Will Van Treuren, Ph.D.

Co-founder and CSO

Will graduated from Stanford in 2020 with his PhD in Microbiology and Immunology. After spending several years in Rob Knight’s lab developing bioinformatic tools, he spent his PhD developing culturomics and small-molecule metabolomics methods to identify microbe and microbe-host co-metabolites.

Our Team

We are a team of passionate experts dedicated to the discovery and development of therapeutics for complex diseases.

Stephanie Tan, Ph.D.

Lead Chemical Biologist

Stephanie Tan, Ph.D.

Lead Chemical Biologist

Stephanie graduated from the University of Toronto in 2022 with her PhD in Biochemistry. Her work focused on identifying microbial products with antibacterial and anti-inflammatory properties using LC-MS.

Geoff Pronovost, Ph.D.

Lead Immunologist

Geoff Pronovost, Ph.D.

Lead Immunologist

Geoff graduated from UCLA in 2022 with his PhD in Molecular Biology. His work focused on describing the role of the maternal microbiome in shaping placental development, identifying microbe-produced metabolites that promote placental growth and vascular development.

Clarisse Roblin, Ph.D.

Lead Biochemist

Clarisse Roblin, Ph.D.

Lead Biochemist

Clarisse earned her Ph.D. in microbiology from Aix-Marseille University in 2020, followed by a post-doctoral position, specializing in the study of antimicrobial peptides, particularly RiPPs. Her work addressed the production, purification and characterization of multifunctional peptides.

Jane Kuszmaul, B.A.

Research Associate

Jane Kuszmaul, B.A.

Research Associate

Jane received her B.A. in Biological Anthropology from California Polytechnic Humboldt and was previously a biology and data science intern at Stanford University’s Sonnenburg Lab.

Lu-min

LCMS Scientist

Lu-min

LCMS Scientist

Missing Bio

Timothy Kao

Research Associate

Timothy Kao

Research Associate

Daniel Mummau

Senior Research Associate

Daniel Mummau

Senior Research Associate

Scientific Advisory Board

Our board has extensive drug development and research experience

Justin Sonnenburg

Full Professor at Stanford University

Justin Sonnenburg

Full Professor at Stanford University

Justin Sonnenburg

Full Professor at Stanford University

Justin Sonnenburg

Full Professor at Stanford University

Microbiome expert and 3X founder

Suzanne Devkota, PhD

Associate Professor at Cedars-Sinai

Suzanne Devkota, PhD

Associate Professor at Cedars-Sinai

Suzanne Devkota, PhD

Associate Professor at Cedars-Sinai

Suzanne Devkota, PhD

Associate Professor at Cedars-Sinai

Access to key clinical samples

Dirk Mendel, PhD

Former VP Pharmacology, KAI Pharmaceuticals

Dirk Mendel, PhD

Former VP Pharmacology, KAI Pharmaceuticals

Dirk Mendel, PhD

Former VP Pharmacology, KAI Pharmaceuticals

Dirk Mendel, PhD

Former VP Pharmacology, KAI Pharmaceuticals

Brought 6 drugs to clinical trial >30 years Pharma Experience

Michael Howell, PhD

Former Director, MedImmune, Incyte

Michael Howell, PhD

Former Director, MedImmune, Incyte

Michael Howell, PhD

Former Director, MedImmune, Incyte

Michael Howell, PhD

Former Director, MedImmune, Incyte

Jessica Ferreyra, PhD

Director Early Clinical Development and Clinical Pharmacology at Organon

Jessica Ferreyra, PhD

Director Early Clinical Development and Clinical Pharmacology at Organon

Jessica Ferreyra, PhD

Director Early Clinical Development and Clinical Pharmacology at Organon

Jessica Ferreyra, PhD

Director Early Clinical Development and Clinical Pharmacology at Organon

Extensive experience with drug development

Derek Maclean, PhD

Former Director of Process Engineering, Amgen

Derek Maclean, PhD

Former Director of Process Engineering, Amgen

Derek Maclean, PhD

Former Director of Process Engineering, Amgen

Derek Maclean, PhD

Former Director of Process Engineering, Amgen

Managed all CMC activities for 5 compounds to commercial readiness

Angele Maki, PhD

Former VP, Director of Business Development, Eli Lilly, Merck, Genetech, BMS

Angele Maki, PhD

Former VP, Director of Business Development, Eli Lilly, Merck, Genetech, BMS

Angele Maki, PhD

Former VP, Director of Business Development, Eli Lilly, Merck, Genetech, BMS

Angele Maki, PhD

Former VP, Director of Business Development, Eli Lilly, Merck, Genetech, BMS

Managed all CMC activities for 5 compounds to commercial readiness

Shake Up Your Career!

Join Us and Make an Impact Today! We are always looking for excited new members. Explore our careers section to learn more.

Learn More